SGRY insider sells shares; proposed 3,145-share sale on NASDAQ
Rhea-AI Filing Summary
Surgery Partners, Inc. (SGRY) submitted a Form 144 notifying a proposed sale of 3,145 common shares through UBS Financial Services with an approximate market value of 65,269.9, and an approximate sale date of 10/09/2025 on NASDAQ. The securities were acquired on 10/09/2025 via equity compensation and paid by equity option exercise.
The filing also lists multiple prior open-market sales by the named person, Wayne DeVeydt, across dates from 08/21/2025 to 10/08/2025, including several large single-day blocks (up to 150,000 shares). The notice includes the required attestation that the seller is not aware of undisclosed material adverse information.
Positive
- Full regulatory disclosure of the proposed sale via Form 144, including acquisition method (equity option exercise)
- Broker identified for the sale: UBS Financial Services, providing execution transparency
Negative
- Multiple insider sales reported from 08/21/2025 to 10/08/2025, including a block of 150,000 shares, which represent material insider liquidity over a short period
- Proposed sale scheduled for 10/09/2025 could add incremental selling supply on NASDAQ
Insights
TL;DR: Multiple recent insider sales and a proposed sale from exercised equity make insider liquidity visible to investors.
The filing shows a proposed sale of 3,145 common shares arising from an equity option exercise and executed via UBS Financial Services on 10/09/2025. The seller also conducted numerous open-market sales between 08/21/2025 and 10/08/2025, including single transactions as large as 150,000 shares.
These items increase publicly visible insider liquidity and help investors track potential supply pressure on the stock; monitor short-term trading volumes and price action around the listed sale dates over the next few trading sessions for any immediate market impact.